Mereo BioPharma Group plc (MREO)
| Market Cap | 55.91M -82.8% |
| Revenue (ttm) | n/a |
| Net Income | -28.10M |
| EPS | -0.18 |
| Shares Out | 159.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,268,974 |
| Open | 0.3980 |
| Previous Close | 0.3880 |
| Day's Range | 0.3500 - 0.3989 |
| 52-Week Range | 0.2000 - 2.3700 |
| Beta | 0.14 |
| Analysts | Buy |
| Price Target | 1.96 (+459.84%) |
| Est. Earnings | Nov 9, 2026 |
About MREO
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an o... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MREO stock is "Buy." The 12-month stock price target is $1.96, which is an increase of 459.84% from the latest price.
News
JPMorgan Downgrades Mereo BioPharma (MREO) Amid Regulatory Concerns, Highlighting Valuation and ...
JPMorgan Downgrades Mereo BioPharma (MREO) Amid Regulatory Concerns, Highlighting Valuation and Growth Challenges
JPMorgan downgrades Mereo to Underweight on regulatory uncertainty
JPMorgan analyst Priyanka Grover last night downgraded Mereo BioPharma (MREO) to Underweight from Neutral without a price target The firm sees regulatory uncertainty for the setrusumab program and add...
Mereo BioPharma downgraded to Underweight from Neutral at JPMorgan
JPMorgan downgraded Mereo BioPharma (MREO) to Underweight from Neutral without a price target
Mereo BioPharma Advances Alvelestat Partnership; Cash Runway Extended Into Late 2027
(RTTNews) - Mereo BioPharma Group plc (MREO), a clinical-stage biopharmaceutical company focused on rare diseases, recently reported its second-quarter 2026 financial results and provided corporate up...
Mereo BioPharma Group Releases Q2 2026 Financial Results
Mereo BioPharma Group plc reported a narrower loss for the second quarter of 2026, though the rare disease specialist recorded no revenue during the period. The post Mereo BioPharma Group Releases Q2 ...
Mereo BioPharma (MREO) Advances Alvelestat Program, Faces Valuation Challenges
Mereo BioPharma (MREO) Advances Alvelestat Program, Faces Valuation Challenges
Mereo BioPharma (MREO) Licenses Alvelestat Rights to Sentynl Therapeutics Amid High Valuation ...
Mereo BioPharma (MREO) Licenses Alvelestat Rights to Sentynl Therapeutics Amid High Valuation and Low Profitability
Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics
(RTTNews) - Sentynl Therapeutics, Inc., a unit of Zydus Lifesciences Limited, on Tuesday said it has entered into an option and license agreement with Mereo BioPharma Group plc (MREO) for U.S. commerc...
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo's investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo and ...
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease On option exercise, Sentynl will have the right to commercialize...
4basebio Announces Appointment of Chief Financial Officer and Board Changes
Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 M...
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced finan...
Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join – Contact Levi & Korsinsky
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO) of a class action securities lawsuit.
MREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO...
MREO DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREO
New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NA...
MEREO LAWSUIT DEADLINE TODAY: Bragar Eagel & Squire, P.C. Urges Mereo BioPharma Stockholders with Large Losses to Contact the Firm Regarding Their Rights
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Mereo (MREO) To Contact Him Directly To Discuss Their Options
MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
NEW YORK--(BUSINESS WIRE)---- $MREO #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc (“Mereo BioPharma” o...
Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO) for violations of §...
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or...
MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
NEW YORK, April 5, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between ...
MREO DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREO
New York, New York--(Newsfile Corp. - April 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NA...
MREO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you purchased or ...
MREO DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREO
New York, New York--(Newsfile Corp. - April 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NA...
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Mereo Bi...
MREO FINAL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO...